All filters
Videos
Early Clinical Phase - Monoclonal Antibodies
Presented at:
European Meeting on HIV & Hepatitis 2022
Videos
Impact of Variants on Clinical Presentation and Outcome in Severe COVID Disease
Presented at:
European Meeting on HIV & Hepatitis 2022
Videos
Dimitrios Paraskevis | European Meeting on HIV & Hepatitis 2022, Day 1
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Seroprevalence of SARS-CoV-2 infection and evolution of humoral immune response in PLWHIV in the Ile-de-France area
B. Abdi Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
HIV-1 Integrase Resistance Associated Mutations and the Use of Dolutegravir in Sub- Saharan Africa: A Systematic Review and Meta-Analysis
E. Semengue Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
HIV transmission clusters in Europe: A perspective view of Late presenters and Non-Late presenters
Mafalda N.S. Miranda Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Characterization of SARS-CoV-2 epidemic and transmission dynamics in children over the four COVID-19 waves
R. Scutari  Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Circulation of sars-cov-2 variants in central Italy: spike variability characterization by deep-sequencing
M. Bellocchi Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
SARS-CoV-2 mutations and variants may muddle the sensitivity of COVID-19 diagnostic assays
M. Alkhatib Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Impact of SARS-CoV-2 omicron and delta sub-lineage AY.4.2 variant on neutralization by sera of patients treated with different licensed monoclonal antibodies
L. Fiaschi Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Levels and durability of humoral and T-specific responses after the booster dose of mRNA BNT162b2 vaccine in residents of a Long Term Care Facility
A. Bergna Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Transmitted drug resistance to integrase based first-line treatment in Europe, 2018-2021
F. Garcia Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
HIV-1 Transmitted drug resistance and transmission clusters in newly diagnosed patients in Portugal between 2014 and 2019
M. Pingarilho Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Reaching the 95-95-95 targets will not eliminate HIV transmission in 2030 among individuals born in sub-Saharan Africa residing in the Netherlands
S. Mukherjee Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
HIV reservoir quantification by combining total HIV-1 DNA assay and intact proviral DNA assay (IPDA) in one triplex digital PCR reaction
M. Delporte Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Temporal trend of drug- resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individuals
D. Armenia Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Comparison of Markers of Inflammation and Associated Baseline Variables in Virologically Suppressed Participants in the TANGO Study at Week 144
R. Wang Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Predictors of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings
D. Armenia Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Analysis of mutational history of multi-drug resistant genotypes with a mutagenetic tree model
M. Pirkl Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Changes in the HIV-1 3'- polypurine tract in patients failing dolutegravir in Brazil
J. Kampen Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Using social media to improve follow-up and routine checks on newly diagnosed young people living with HIV and their adherence to Antiretroviral Therapy
K. Owoso Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Resistance analysis of pre- treatment NS3 and NS5A variants in HCV genotype 1a, 1b and 3a infected patients in Croatia
P. Simicic Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Evaluation of the virological efficacy of switching to dolutegravir-based tritherapy in patients followed under real-life conditions in Abidjan, Côte d'Ivoire
J. Dechi Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022
Abstracts
Major protease resistance in West African HIV-1 subtypes is associated with novel protease mutations and accelerated gag evolution during second-line ART
K. Bouzidi Reviews in Antiviral Therapy & Infectious Diseases 3, 2022
Presented at:
European Meeting on HIV & Hepatitis 2022